213 related articles for article (PubMed ID: 15149035)
1. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
3. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
Cornford-Nairns R; Daggard G; Mukkur T
J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
[TBL] [Abstract][Full Text] [Related]
4. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
[TBL] [Abstract][Full Text] [Related]
5. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
[TBL] [Abstract][Full Text] [Related]
6. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
8. The BvgAS Regulon of
Moon K; Bonocora RP; Kim DD; Chen Q; Wade JT; Stibitz S; Hinton DM
mBio; 2017 Oct; 8(5):. PubMed ID: 29018122
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.
Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH
Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136
[No Abstract] [Full Text] [Related]
10. Is there a need for a new generation of vaccines against pertussis?
Storsaeter J; Wolter J
Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
[TBL] [Abstract][Full Text] [Related]
11. The Role of Mucosal Immunity in Pertussis.
Solans L; Locht C
Front Immunol; 2018; 9():3068. PubMed ID: 30692990
[TBL] [Abstract][Full Text] [Related]
12. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
Lim A; Ng JK; Locht C; Alonso S
Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
[TBL] [Abstract][Full Text] [Related]
13. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
Mielcarek N; Debrie AS; Mahieux S; Locht C
Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
[TBL] [Abstract][Full Text] [Related]
14. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
[TBL] [Abstract][Full Text] [Related]
16. Molecular aspects of Bordetella pertussis pathogenesis.
Locht C
Int Microbiol; 1999 Sep; 2(3):137-44. PubMed ID: 10943406
[TBL] [Abstract][Full Text] [Related]
17. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
18. Investigating pertussis toxin and its impact on vaccination.
Coutte L; Locht C
Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536
[TBL] [Abstract][Full Text] [Related]
19. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
[TBL] [Abstract][Full Text] [Related]
20. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.
Bart MJ; Harris SR; Advani A; Arakawa Y; Bottero D; Bouchez V; Cassiday PK; Chiang CS; Dalby T; Fry NK; Gaillard ME; van Gent M; Guiso N; Hallander HO; Harvill ET; He Q; van der Heide HG; Heuvelman K; Hozbor DF; Kamachi K; Karataev GI; Lan R; Lutyńska A; Maharjan RP; Mertsola J; Miyamura T; Octavia S; Preston A; Quail MA; Sintchenko V; Stefanelli P; Tondella ML; Tsang RS; Xu Y; Yao SM; Zhang S; Parkhill J; Mooi FR
mBio; 2014 Apr; 5(2):e01074. PubMed ID: 24757216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
